These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11094319)

  • 1. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ; Pinedo HM; Smid K; Comijn EM; Voorn DA; Veerman G; Lakerveld B; Van der Vijgh WJ; Giaccone G; Postmus PE; Peters GJ
    Eur J Cancer; 2000 Dec; 36(18):2420-9. PubMed ID: 11094319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
    van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
    Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
    van Moorsel CJ; Pinedo HM; Veerman G; Vermorken JB; Postmus PE; Peters GJ
    Eur J Cancer; 1999 May; 35(5):808-14. PubMed ID: 10505043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
    Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ; Smid K; Voorn DA; Bergman AM; Pinedo HM; Peters GJ
    Int J Oncol; 2003 Jan; 22(1):201-7. PubMed ID: 12469205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Guechev A; Smid K; Loves WJ; Vermorken JB; Postmus PE; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):407-15. PubMed ID: 9933029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
    Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study.
    Saad SY; Najjar TA; Noreddin AM; Al-Rikabi AC
    Pharmacol Res; 2001 Feb; 43(2):193-8. PubMed ID: 11243722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
    Padrón JM; van Moorsel CJ; Bergman AM; Smitskamp-Wilms E; van der Wilt CL; Peters GJ
    Anticancer Drugs; 1999 Jun; 10(5):445-52. PubMed ID: 10477163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
    Yang LY; Li L; Jiang H; Shen Y; Plunkett W
    Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
    Teicher BA; Pfeffer MR; Alvarez Sotomayor E; Herman TS
    Int J Hyperthermia; 1991; 7(5):773-84. PubMed ID: 1834752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
    Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
    Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
    Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
    Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.